Apricus Biosciences Announces 2010 Year End Financial Results Conference Call
09 mars 2011 09h30 HE
|
Seelos Therapeutics, Inc.
SAN DIEGO, March 9, 2011 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio") (Nasdaq:APRI) announced today that management will hold a conference call to discuss its 2010 year end financial...
Apricus Biosciences Announces Removal of Auditor's "Going Concern" Opinion From Its 2010 Form 10-K and Increased Cash Reserves
08 mars 2011 09h57 HE
|
Seelos Therapeutics, Inc.
SAN DIEGO, March 8, 2011 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio") (Nasdaq:APRI) announced today that the going concern paragraph has been removed from its audit opinion contained...
Apricus Biosciences Announces Expanded European Patent Coverage for MycoVa(TM) for Nail Fungus
01 mars 2011 09h14 HE
|
Seelos Therapeutics, Inc.
SAN DIEGO, March 1, 2011 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio") (Nasdaq:APRI) announced today that the European Patent Office ("EPO") will grant a patent for the company's...
Apricus Biosciences and FDA Initiate PrevOnco(TM) SPA Phase III Clinical Protocol Discussion
17 févr. 2011 09h11 HE
|
Seelos Therapeutics, Inc.
SAN DIEGO, Feb. 17, 2011 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio") (Nasdaq:APRI), announced today that it is currently in discussions with the U.S. Food and Drug Administration...
Apricus Biosciences and Neopharm Group Sign Licensing Agreement for Vitaros(R) in Israel for up to $4.35 Million, Plus Royalties
14 févr. 2011 10h14 HE
|
Seelos Therapeutics, Inc.
SAN DIEGO, Feb. 14, 2011 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio") (Nasdaq:APRI), announced today that it has entered into a licensing agreement granting Neopharm Group...
Apricus Biosciences to Present Review of Commercialization Plans for Vitaros(R) and Development of Product Pipeline at BioPartnering North America Conference(TM)
10 févr. 2011 10h14 HE
|
Seelos Therapeutics, Inc.
SAN DIEGO, Calif., Feb. 10, 2011 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio") (Nasdaq:APRI), (http://www.apricusbio.com) today announced that Linda Smibert, Vice President, Business...
Apricus Biosciences Presents Data on Oral Use of Nexact(R) Technology at the Controlled Release Society Conference
28 janv. 2011 09h52 HE
|
Seelos Therapeutics, Inc.
SAN DIEGO, Jan. 28, 2011 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio") (Nasdaq:APRI), (http://www.apricusbio.com) today announced that its research and development team at its...
Apricus Biosciences' Chief Executive Officer is Interviewed on CDTV.net
26 janv. 2011 10h02 HE
|
Seelos Therapeutics, Inc.
SAN DIEGO, Jan. 26, 2011 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio") (Nasdaq:APRI) (http://www.apricusbio.com) announced today that Chief Executive Officer, Dr. Bassam...
Apricus Biosciences Reports Additional Analysis Showing That MycoVa(TM) is as Effective for the Treatment of Nail Fungus as the Current European Standard of Care for Topical Therapy, Loceryl(R)
19 janv. 2011 11h41 HE
|
Seelos Therapeutics, Inc.
SAN DIEGO, Jan. 19, 2011 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio") (Nasdaq:APRI) today announced that an additional analysis conducted on behalf of the Company has shown that...
Apricus Bio Announces Expansion of Patent Portfolio for Topical Cream to Treat Premature Ejaculation With Issuance of Japanese Patent
14 janv. 2011 12h03 HE
|
Seelos Therapeutics, Inc.
SAN DIEGO, Jan. 14, 2011 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc., ("Apricus Bio") (Nasdaq:APRI) today announced that the Japanese Patent Office recently issued a Decision to Grant a Patent for...